Methods for modulating ikkalpha activity

ABSTRACT

A method for modulating NF-κB dependent gene transcription in a cell comprised of modulating IKKα protein activity in the cell. The present invention also provides siRNA compositions and methods thereof for modulating NF-κB dependent gene transcription.

CROSS-REFERENCE TO RELATED APPLICATIONS

This patent application is a Continuation of U.S. Ser. No. 10/730,614,filed Dec. 8, 2003, which is a non-provisional patent application ofU.S. 60/431,825, filed Dec. 9, 2002, both of which are incorporatedherein in their entirety.

BACKGROUND OF THE INVENTION

This invention relates to the field of, inflammatory diseases andautoimmune diseases and the treatment thereof through the modulation ofIKKα activity and the modulation of genes under the control of IKKα.

BACKGROUND INFORMATION

The NF-κB or nuclear factor κB is a transcription factor that plays acritical role in inflammatory diseases by inducing the expression of alarge number of proinflammatory and anti-apoptotic genes. These includecytokines such as IL-1, IL-2, IL-11, TNF-α and IL-6, chemokinesincluding IL-8, GRO1 and RANTES, as well as other proinflammatorymolecules including COX-2 and cell adhesion molecules such as ICAM-1,VCAM-1, and E-selectin. Pahl H L, (1999) Oncogene 18, 6853-6866; Jobinet al, (2000) Am. J. Physiol. Cell. Physiol. 278: 451-462. Under restingconditions, NF-κB is present in the cytosol of cells as a complex withIκB. The IκB family of proteins serve as inhibitors of NF-κB,interfering with the function of its nuclear localization signal (seefor example U. Siebenlist et al, (1994) Ann. Rev. Cell Bio., 10: 405).Upon disruption of the IκB-NF-κB complex following cell activation,NF-κB translocates to the nucleus and activates gene transcription.Disruption of the IκB-NF-κB complex and subsequent activation of NF-κBis initiated by degradation of IκB.

Activators of NF-κB mediate the site-specific phosphorylation of twoamino terminal serines in each IκB which makes nearby lysines targetsfor ubiquitination, thereby resulting in IκB proteasomal destruction.NF-κB is then free to translocate to the nucleus and bind DNA leading tothe activation of a host of inflammatory response target genes. Baldwin,A., Jr., (1996) Annu Rev Immunol 14: 649-683, Ghosh, S. et al, (1998)Annu Rev Immunol 16, 225-260. Recent evidence has shown that NF-κBsubunits dynamically shuttle between the cytoplasm and the nucleus but adominant acting nuclear export signal in IκBα ensures their transportback to the cytoplasm.

Even though NF-κB is largely considered to be a transcriptionalactivator, under certain circumstances it can also be involved indirectly repressing gene expression (reviewed in Baldwin, A., Jr.,(1996) Annu. Rev. Immunol., 14: 649-683; Ghosh, S. et al. (1998) Annu.Rev. Immunol., 16: 225-260).

The phosphorylation of IκB is a major triggering event in regulation ofthe NF-κB pathway. Since the abnormal regulation of the NF-κB pathway isknown to correlate with inflammatory disease, the regulation of IκBphosphorylation is understood as an important area for diseaseintervention. The search for the kinase responsible for the induciblephosphorylation of IκB has been one of the major focuses in the NF-κBfield. IκB phosphorylation is mediated by a high molecular weightsignalsome complex consisting of at least three components: two IκBkinases IKKα, IKKβ and a non-catalytic regulatory subunit NEMO (reviewedin Mercurio, F. et al, (1999) Oncogene, 18: 6163-6171; Barkett, M. etal, (1999) Oncogene, 18: 6910-6924; Karin, M., (1999) Oncogene, 18:867-6874). A great deal of study has been performed to determine therespective roles that each of the components play in the regulation ofNF-kB with the belief that a greater understanding of the roles mightlead to the development of new methods and approaches for the treatmentof inflammatory diseases. Two molecules of NEMO are believed toorchestrate the assembly of the IKKs into the high molecular weightsignalsome complex at least in part by binding to specificcarboxy-terminally conserved residues of both IKKα and IKKβ termed theNEMO binding domain or NBD. Krappmann, D. et al, (2000) J. Biol Chem275: 29779-29787; Li, X. H. et al, (2001) J. Biol. Chem., 276:4494-4500; Hatada, E. N. et al, (2000) Current Opinion in Immunology,12: 52-58; May, M. J. et al, (2000) Science, 289: 1550-1554. NEMO mayalso facilitate the recruitment of IκBα to the IKK complex. Yamamoto, Y.et al, (2001) J. Biol. Chem., 276: 36327-36336. The two catalytic IKKsubunits differentially respond via NEMO to an array of signal induced,upstream kinase activities culminating in the coordinatedphosphorylation of a pair of serines in their MAPK-like T activationloops by an unknown mechanism.

The roles of the IKKs in NF-κB activation were studied in mice lackingIKKβ, IKKα or NEMO. Li, Q. et al, (1999) Science, 28: 321-325; Li, Z. etal (1999) J. Exp. Med. 189: 1839-1845; Tanaka, M. et al, (1999)Immunity, 10: 421-429; Li, Q. et al, (1999) Genes Dev., 13: 1322-1328;Hu, Y. et al. (1999) Science, 284: 316-320; Takeda, K. et al, (1999)Science, 284: 313-316. Akin to mice genetically deficient for the NF-κBp65 subunit (Beg, A. A. et al, (1995) Nature, 376: 167-170), murineembryos genetically null for either IKKβ or NEMO succumbed to severeliver apoptosis in utero due to a virtually complete block in NF-κBactivation. Li, Q. et al, (1999) Science, 284: 321-325; Li, Z. et al.(1999) J. Exp. Med., 189: 1839-1845; Tanaka, M. et al, (1999) Immunity,10: 421-429; Rudolph, D. et al, (2000) Genes and Dev. 14: 854-862;Schmidt-Supprian, M. et al, (2000) Mol. Cell, 5: 981-992; Makris, C. etal, (2000) Mol. Cell, 5: 969-979. These IKKβ and NEMO KO animals wereseverely if not completely deficient for both cytokine mediated IκBdegradation and nuclear NF-κB DNA binding activity. Li, Q. et al, (1999)Science, 284: 321-325; Li, Z. et al, (1999) J. Exp. Med. 189: 1839-1845;Tanaka, M. et al, (1999) Immunity, 10: 421-429; Rudolph, D. et al.(2000) Genes and Dev., 14: 854-862; Schmidt-Supprian, M. et al, (2000)Mol. Cell, 5: 981-992; Makris, C. et al, (2000) Mol. Cell. 5: 969-979.

In contrast, to the IKKβ and NEMO KO mice, IKKα null animals diedperinatally due to severe skin, limb and skeletal abnormalities causedby a block in the terminal differentiation of epidermal kerotinocytes.Li, Q. et al, (1999) Genes Dev. 13: 1322-1328; Hu, Y. et al, (1999)Science, 284: 316-320; Takeda, K. et al. (1999) Science, 284: 313-316.Subsequent work revealed that IKKα, (independent of both its kinaseactivity and NF-κB), controls the production of a soluble factor thatinduces kerotinocyte differentiation. Hu, Y., Baud, V. et al, (2001)Nature, 410: 710-714. Furthermore, IKKα null embryos appeared to bephenotypically normal for both cytokine induced IκBα degradation, NF-κBnuclear translocation and NF-κB DNA binding activity. Hu, Y. et al,(1999) Science, 284: 316-320; Takeda, K. et al, (1999) Science, 284:313-316. In addition, an independent study in cultured mammalian cellsemploying transfection conditions that avoided over-expression artifactsconcluded that the cytokine controlled activation of NF-κB induction wasan in vivo function of IKKβ and not IKKα. Delhase, M. et al, (1999)Science, 284: 309-313.

This body of work has led to the well-accepted belief in the art thatIKKβ alone is essential for NF-κB activation by inflammatory responsemediators. Karin, M. (1999) Oncogene, 18: 6867-6874; Hatada, E. N. etal, (2000) Current Opinion in Immunology, 12: 52-58; Karin, M. et al.(2000) Annu. Rev. Immunol., 18: 621-663. More recently and in keepingwith its separate and distinct functions from IKKβ, IKKα has been shownto possess at least two additional novel in vivo functions: (a) it isessential for B lymphocyte maturation (Kaisho, T. et al, (2001) J. Exp.Med. 193: 417-426) and Peyers patch formation via an LTβR and NIKdependent signaling pathway (Matsushima, A. et al, (2001) J. Exp. Med.193: 631-636), wherein it is required to target the cytokine inducedprocessing of the NF-κB2 (p100) precursor to produce the functionalNF-κB p52 subunit (Senftleben, U. et al, (2001) Science, 293: 1495-1499)and (b) it is required for the proliferation of mammary epithelial cellsin response to RANK ligand but not TNFα signaling to activate cyclin D1.Cao, Y., Bonizzi, G. et al, (2001) Cell, 107: 763-775. Independent ofthese studies, IKKβ was reported to phosphorylate an IκB-likedestruction motif in p50' s p105 precursor, which produces a recognitionsite for βTrCP-containing SCF ubiquitin ligases with subsequentpolyubiquination of p105 causing its complete proteasomal destructionand the induced release of DNA binding p50 homodimers (Heissmeyer, V. etal, (1999) Embo. J., 18: 4766-4778; Heissmeyer, V. et al, (2001) Mol.Cell. Biol., 21: 1024-1035), providing additional support for the notionthat IKKβ and IKKα have distinct roles in NF-κB activation.

In addition to the well accepted belief of induced nuclear translocationof NF-κB dependent gene expression, an alternative mechanism has emergedthat involves the phosphorylation of the p65 transactivation subunit.The protein kinase A catalytic subunit phosphorylates p65 which leads tothe association of p65 and the p300 transcriptional coactivator. Zhong,H. et al, Mol. Cell, (1998) 1: 661-671. Cells from GSK3 and T2K knockoutmice are capable of inducing NF-κB nuclear translocation but aredeficient in stimulating transactivation functions of NF-κB. Hoeflich etal, (2000) Nature, 406: 86-90; Bonnard, M. et al, (2000) Embo. J., 19:4976-4985. Thus, NF-κB dependent gene transcription is regulated atother step(s) in addition to IκBα degradation and NF-κB translocation.

Recently, it has been shown that in mouse embryonic fibrolasts, IKKα isrequired for NF-κB-mediated gene transcription in response toproinflammatory cytokine TNFα and IL-1β. Li, X. et al, (2002) J. Biol.Chem., 277: 45129-45140. This is in dramatic contrast to the generallyaccepted view of IKKα being dispensable for TNF and IL-1 induced genetranscription mediated by NF-κB. Hu, Y. et al, (1999) Science, 284:316-320; Takeda, K. et al, (1999) Science, 284: 313-316. One way todemonstrate that IKKα is also needed for TNFα-induced NF-κB dependentgene transcription in human cells, is to specifically knock down theexpression or activity of IKKα.

The function of a gene can be determined on the basis of the behavior ofcells in which the level of gene expression or level of activity of thegene product has been reduced. Experimental procedures can be used tospecifically inactivate or silence a target gene or inhibit the activityof its gene product Inhibition of protein activity can be brought aboutat the level of gene transcription, protein translation or posttranslational modifications. For instance, the activity of a protein canbe inhibited by directly inhibiting the activity of the protein such asaltering a catalytic domain or alternatively by reducing the amount ofthe protein in the cell by reducing the amount of mRNA encoding theprotein. In each case the level of protein activity in the cell isreduced. Various techniques can be used to knock down the activity of aprotein and these include knockout technologies (antibodies, antisenseRNA, and RNA interference) and compounds that specifically inhibit theprotein activity. Antisense RNAs directed to IKKα has been reported foruse in the inhibition of IKKα expression. U.S. Pat. No. 6,395,545.

It is anticipated that compounds capable of modulating the expression ofIKKα, and/or modulating the activity of IKKα may provide for a novelclass of agents with activity toward a variety of inflammatory andautoimmune diseases such as osteoarthritis, reperfusion injury, asthma,multiple sclerosis, Guillain-Barre syndrome, Crohn's disease, ulcerativecolitis, psoriasis, graft versus host disease, systemic lupuserythematosus, rheumatoid arthritis, Alzheimer's disease, toxic shocksyndrome, inflammatory bowel disease, insulin-dependent diabetesmellitis, acute and chronic pain as well as symptoms of inflammation andcardiovascular disease, stroke, myocardial infarction alone or followingthrombolytic therapy, thermal injury, adult respiratory distresssyndrome (ARDS), multiple organ injury secondary to trauma, acuteglomerulonephritis, dermatoses with acute inflammatory components, acutepurulent meningitis or other central nervous system disorders, Grave'sdisease, myasthenia gravis, scleroderma and atopic dermatitis.

RNA interference (RNAi) is a technique that can be used to knockdown theactivity of genes and their protein products in a specific manner. RNAiwas first used in the Nematode worm Caenorhabditis elegans as a responseto double stranded RNA (dsRNA) that resulted in the gene knockdownspecific manner. Fire, A. et al, (1998) Nature, 391: 806-811. RNAi is aprocess whereby a double stranded RNA (dsRNA) of a sequence that ishomologous to a target gene can be used to cause the degradation ofmessenger RNA (mRNA) transcribed from that target gene. Sharp, P. A.,(2001) Genes Dev., 15: 485-490. Initiation of gene silencing or geneinactivation occurs upon recognition of dsRNA by the cells machinerythat convert the silencing trigger to 21-25 nucleotides RNAs. Hannon,(2002) Nature, 418: 244-250.

The mediators of sequence-specific messenger RNA degradation are 21- and22-nucleotide small interfering RNAs (siRNAs) generated by ribonucleaseIII cleavage from longer dsRNAs. In vitro synthesized 21-nucleotidesiRNA duplexes specifically suppress expression of endogenous andheterologous genes in different mammalian cell lines, including humanembryonic kidney and HeLa cells. Elbashir S. et al, (2001) Nature, 411:494-498. Therefore, 21-nucleotide siRNA duplexes provide a new tool forstudying gene function in mammalian cells and may be used asgene-specific therapeutics. However, effective gene silencing is onlycaused by a subset of siRNAs complementary to the mRNA target. McManus MT et al, (2002) J. Immunol. 169: 5754-60. Thus, design of multiple siRNAoligos and extensive testing are required to obtain a potent siRNAoligo. McManus M T et al, (2002) J. Immunol. 169: 5754-60.

The ability to specifically knock down expression of a target gene by siRNA has many benefits. For example si RNA could be used to mimic truegenetic knockout animals to study gene function. There have been reportsof using siRNA for various purposes including the inhibition ofluciferase gene expression in human cells, (see US Patent ApplicationNo. 2002/0132788); HIV-1 Cellular receptor CD4 (Sharp et al, (2002)Nature Medicine, 8: 681-686); HIV accessory genes, vif and nef (NatureAdvance Online Publication, Jun. 26, 2002 (doi:10.1038/nature00896); HPVE6 and E7 gene expression. Jiang M., Oncogene, (2002), 21:6041-6048);Subtype- and species-specific knockdown of protein kinase C (Irie N. etal, Biochem. Biophys. Res. Commun., (2002) 298: 738-743.

BRIEF SUMMARY OF THE INVENTION

A first embodiment of the invention provides a method for modulatingNF-κB dependent gene transcription in a cell, said method comprised ofmodulating IKKα activity in the cell.

A second embodiment of the invention provides for selectively modulatingexpression of a gene whose transcription is regulated by IKKα, themethod comprising modulating IKKα activity such that expression of thegene is modulated.

A third embodiment of the invention provides for modulating NF-κBdependent gene transcription by administration of siRNA directed to IKKαto cells. SiRNA can be 21 to 25 nucleotides in length and hybridize to anucleic acid molecule encoding human IKKα.

A fourth embodiment of the invention provides a method for treatingautoimmune and inflammatory disease in a mammal wherein the method iscomprised of modulating IKKα expression or IKKα activity.

A fifth embodiment of the invention provides a method for treatingautoimmune and inflammatory disease in a mammal wherein the method iscomprised of modulating IKKα expression or IKKα activity byadministration of siRNA directed to IKKα.

A sixth embodiment of the invention provides a method for reducing theeffects of TNFα induced genes in cells, the method comprised of reducingIKKα activity in a cell.

A seventh embodiment of the invention provides a method for reducing theeffects of NF-κB induced gene transcription, the method comprised ofreducing IKKα activity in a cell.

An eighth embodiment of the invention provides a siRNA composition thatwhen administered to a cell modulates IKKα activity.

A ninth embodiment of the invention provides a method for identifying acompound for the treatment of autoimmune and inflammatory disease, saidmethod comprised of the steps of:

-   -   1) incubating an IKKα protein in the presence of a potential        inhibitor of IKKα activity;    -   2) measuring the loss of IKKα activity;    -   3) comparing the amount of IKKα activity present in the absence        of a potential inhibitor.

Either the fully encoded IKKα or a fragment thereof can be used in themethod for identifying a compound for the treatment of autoimmune andinflammatory disease.

One particular advantage of using inhibitors specific to IKKα in thepresent invention is that such inhibitors may have less side effectssuch as liver apoptosis as compared to inhibitors for IKKβ and NEMO.Other features and advantages of the invention will be apparent from thefollowing detailed description of the invention.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows the effect of IKKα and IKKβ mRNA expression in HeLa cellsafter administration of siRNA directed to IKKα.

FIG. 2 shows siRNA directed to IKKα inhibits IKKα, IL-6 and IL-8expression in HeLa cells.

FIG. 3 shows IKKα siRNA inhibits NF-κB activity in HeLa cellstransfected with luciferase reporter gene.

DETAILED DESCRIPTION OF THE INVENTION I. General Description

The present invention provides a method for modulating NF-κB dependentgene transcription, said method comprised of the step of modulating IKKαprotein activity in a cell. The level of IKKα protein activity in a cellcan be modulated upward or downward. The level of IKKα activity ispreferentially modulated downward. One embodiment of the invention isbased in part on the demonstration that the use of an IKKα specificinhibitor in TNFα stimulated human cells results in the modulation ofgenes under the influence of NF-κB.

The present invention employs siRNA for use in modulating the level ofIKKα protein activity in the cell. SiRNA oligonucleotides directed toIKKα specifically hybridize nucleic acids encoding IKKα and interferewith IKKα gene expression. Accordingly, IKKα proteins levels are reducedand the total level of IKKα activity in the cell is reduced. Since IKKαhas been shown to play a role in triggering the NF-κB pathway (Table I;Li, X. et al, (2002) J. Biol. Chem., 277: 45129-45140), which functionsin the inflammatory response, compounds that have the property of beingable to specifically and effectively inhibit IKKα are understood to behelpful in the treatment of autoimmune and inflammatory diseases.

Without intending to be limited by mechanism, it is believed that anIKKα specific inhibitor acts by reducing the amount of activity of IKKαprotein and or IKKα expression in a cell, thereby directly or indirectlyreducing the phosphorylation of NF-κB p100 Pomerantz, J. L. andBaltimore, D., Mol. Cell, (2002) 10:693-5) or NF-κB p65. Sizemore, N. etal, J. Biol. Chem., (2002) 277: 3863-9.

The present invention also provides methods for treating inflammatoryand autoimmune diseases using inhibitors of IKKα activity and is basedin part on the demonstration that the expression of proinflammatorygenes under the influence of the NF-κB pathway can be inhibited uponadministering IKKα specific inhibitors to a cell. NF-κB dependent genesare found to be over expressed in autoimmune and inflammatoryconditions. Barnes et al, (1997) New England J. Med., 336: 1066-1071; US2002/0156000; U.S. Pat. Nos. 6,395,545; 6,440,973; WO 02/060386incorporated herein by reference.

The present invention also provides methods for identifying compoundsthat modulate the activity of IKKα for the treatment of autoimmune andinflammatory disease.

DEFINITIONS

Unless defined otherwise, the scientific and technological terms andnomenclature used herein have the same meaning as commonly understood bya person of ordinary skill in the art to which this invention pertains.

Nucleotide sequences are presented herein by a single strand, in the 5′to 3′ direction, from left to right, using the one letter nucleotidesymbols as commonly used in the art and according with therecommendations of the IUPAC-IUB Biochemical Nomenclature Commission(1972).

The term “IKKα” as it is used herein refers to the alpha subunit of theIκB kinase complex. IKKα is a kinase that phosphorylates IκB, NF-κB p100or other protein substrates.

The term “gene transcription” as it is used herein means a processwhereby one strand of a DNA molecule is used as a template for synthesisof a complementary RNA by RNA polymerase.

The term “DNA” as used herein refers to polynucleotide molecules,segments or sequences and is used herein to refer to a chain ofnucleotides, each containing the sugar deoxyribose and one of the fouradenine (A), guanine (G) thymine (T) or cytosine (C).

The term “RNA” as used herein refers to polynucleotide molecules,segments or sequences and is used herein to refer to a chain ofnucleotides each containing the sugar ribose and one of the four adenine(A), guanine (G) uracil (U) or cytosine (C).

The term “oligo” as used herein means a short sequence of DNA or DNAderivatives typically 8 to 35 nucleotides in length. An oligonucleotidecan be derived synthetically, by cloning or by amplification. The term“derivative” is intended to include any of the above described variantswhen comprising an additional chemical moiety not normally a part ofthese molecules. These chemical moieties can have varying purposesincluding, improving solubility, absorption, biological half life,decreasing toxicity and eliminating or decreasing undesirable sideeffects.

The term “specifically hybridize” as used herein means that underappropriate conditions a probe made or a nucleic acid sequence such asan siRNA oligo hybridizes, duplexes or binds only to a particular targetDNA or RNA sequence present in a cell or preparation of DNA or RNA. Aprobe sequence such as an siRNA sequence specifically hybridizes to atarget sequence when the base sequence of the probe nucleic acid and thetarget sequence are complimentary to one another. The target sequenceand the probe sequence do not have to be exactly complimentary to oneanother in order for the probe sequence to specifically hybridize. It isunderstood that specific hybridization can occur when the target andprobe sequences are not exactly complimentary to one another andspecific hybridization can occur when up only about 80% of the bases arecomplimentary to one another. Preferably, it is understood that inspecific hybridizations probe and target sequence have 80%comprehensibility to one another. For discussions on hybridization seefor example, Current Protocols in Molecular Biology, F. Ausubel et al.,(ed.) Greene Publishing and Wiley-Interscience, New York (July, 2002).

The term “RNAi” as used herein means RNA interference process for asequence-specific post-transcriptional gene silencing or gene knockdownby providing a double-stranded RNA (dsRNA) that is homologous insequence to the targeted gene. Small interfering RNAs (siRNAs) can besynthesized in vitro or generated by ribonuclease III cleavage fromlonger dsRNA and are the mediators of sequence-specific mRNAdegradation.

The term “modulating IKKα activity” as used herein means eitherinhibiting (decreasing) or stimulating (increasing) the level ofactivity of IKKα protein in a cell. IKKα activity can be modulated bymodification of the levels and/or activity of IKKα protein, or bymodification of the level of IKKα gene transcription and/or IKK 2activity structure such that the levels of IKKα protein activity in thecell is modulated. In the context of the present invention, inhibitionis the preferred form of modulation.

The term “autoimmune and inflammatory disease” as used herein meansdiseases that are associated with autoimmune and inflammatory conditionssuch as inflammatory and autoimmune conditions such as osteoarthritis,reperfusion injury, asthma, multiple sclerosis, Guillain-Barre syndrome,Crohn's disease, ulcerative colitis, psoriasis, graft versus hostdisease, systemic lupus erythematosus, rheumatoid arthritis, Alzheimer'sdisease, toxic shock syndrome, insulin-dependent diabetes mellitis,acute and chronic pain as well as symptoms of inflammation andcardiovascular disease, stroke, myocardial infarction alone or followingthrombolytic therapy, thermal injury, adult respiratory distresssyndrome (ARDS), multiple organ injury secondary to trauma, acuteglomerulonephritis, dermatoses with acute inflammatory components, acutepurulent meningitis or other central nervous system disorders, Grave'sdisease, myasthenia gravis, scleroderma and atopic dermatitis.

The term “protein fragment” as used herein means a truncated form of aprotein. For IKKα suitable protein fragments should include the kinasedomain understood as extending from at least amino acid residues 15 to293 (SEQ. ID No. 2).

The term “protein” as used herein means isolated naturally occurringpolypeptides, recombinantly produced proteins. Means for preparing suchproteins are well understood in the art. Proteins may be in the form ofthe secreted protein, including truncated or mature forms. Proteins mayoptionally be modified to include an additional amino acid sequencewhich contains secretory or leader sequences, pro-sequences, sequenceswhich aid in purification, such as multiple histidine residues, or anadditional sequence for stability during recombinant production. Theproteins of the present invention are preferably provided in an isolatedform, and preferably are substantially purified. A recombinantlyproduced version of a protein, including the secreted protein, can besubstantially purified using techniques described herein or otherwiseknown in the art, such as, for example, by the one-step method describedin Smith et al, Gene, 67:31-40 (1988). Proteins of the invention alsocan be purified from natural, synthetic or recombinant sources usingtechniques described herein or otherwise known in the art.

The term “Gene knockdown” as used herein refers to the reduction in theactivity of a gene. The term “gene silencing” or gene inactivation areconsidered to have the same meaning as the terms are used herein.

The term “potential inhibitor of IKKα activity” as used herein means anycompound or molecule that can cause the inhibition of IKKα activity. Theinhibition of IKKα activity should be specific to IKKα. Potential IKKαinhibitors can be compounds that block, antagonize, prevent, or reducethe activation of IKKα. IKKα inhibitors inhibit the activity of IKKα,preferably the in vivo activity, such that the catalytic activity ofIKKα is inhibited 2) the phosphorylation of p100 or NF-κB, p65 or IκB isinhibited or 3) NF-κB dependent proinflammatory genes are inhibited.SiRNA as well as small molecule inhibitors directed to IKKα can bepotential inhibitors of IKKα activity.

The term “proinflammatory gene” as used herein refers to any gene thatis induced upon an inflammatory response through the NF-κB pathway.Examples of proinflammatory genes include but are not limited to betainhibin, IL-8, IL-6, interferon stimulated protein, TNF-induced protein,Cox2, GRO1 oncogene, CD44, interleukin 11, and superoxide dismutase.

The term “specific inhibitor” as used herein means an inhibitor thatinhibits one protein more than another protein. For example, a potentialinhibitor of IKKα is considered to be specific for IKKα over anotherIKKβ protein when there is preferably at least 10 to 100 fold or greaterand most preferably about 1000 fold difference in inhibition of IKKαcompared to IKKβ.

The term “NF-κB gene transcription” as used herein means genes that areeither upregulated or downregulated in response to the level of NF-kBactivity in a cell. Such genes include, but are not limited to IL-6,IL-8, inhibin, beta A, intercellular adhesion molecule 1, interferonstimulated protein, Cox2, IL-11, GRO1 and superoxide dismutase. NF-κBdependent genes are also discussed in US 2002/0156000: Barnes et al.(1997) New England J. Med. 336: 1066-1071; Pahl H L, Oncogene, (1999),18, 6853-6866 incorporated herein by reference.

The term “delivery” as used herein refers to the introduction of foreignmolecule (i.e. nucleic acid small molecule inhibitor) in cells.

The term “treating” as used herein means the prevention, reduction,partial or complete alleviation or cure of a disease.

Using the present invention it is possible to observe the function ofIKKα. In addition, specific siRNA oligos directed to IKKα have beendesigned and tested in human cells showing a reduction in the expressionof proinflammatory genes and NF-κB target genes with their use. ThesesiRNA and equivalent compounds may have therapeutic value in thetreatment of autoimmune and inflammatory disease as described herein. Itis therefore understood that compounds that inhibit either IKKαexpression or IKKα protein activity also have therapeutic value.

The term “Administration” as used herein means the introduction of aForeign molecule (i.e. nucleic acid, small molecule inhibitor) into acell. The term is intended to be synonymous with the term “Delivery”.

III. Specific Embodiments

Preferred aspects of embodiments of the present invention are describedin the following examples, which are not to be construed as limiting.

In one embodiment the method of the invention is used to reduce NF-κBdependent gene expression in a cell, said method comprised of reducingIKKα protein activity in a cell. The level of NF-κB dependent geneexpression is proportionate to the level of IKKα activity in the cell.In other words, when the level of IKKα activity is lowered the level ofexpression of proinflammatory NF-κB dependent genes is also reduced.

The method of the invention can comprise modulating NF-κB dependent geneexpression in a cell by administration of siRNA directed to IKKα. RNAinterference is a method whereby siRNA can be used to knockdown orreduce the level of expression of a specific gene. In the case of IKKα,siRNA specifically directed to IKKα can be administered to cells inorder to knockdown IKKα protein activity in the cell and to reduce theexpression of NF-κB proinflammatory genes. SiRNA can be designedaccording to the technique described by Tuschl, described as follows.Elbashir, S M et al, Nature, 2001, 411, 494-498. SiRNA that canefficiently knockdown a gene can be obtained by using siRNA duplexescomposed of 21 nt sense and 21 nt antisense strands paired in a mannerto have a 2-nt 3′ overhang. The sequence of the 2-nt overhang is thoughtto make a contribution to the specificity of the target recognitionrestricted to the unpaired nucleotide adjacent to the first base pair.2-Deoxynucleotides are used in the 3′ overhang.

The targeted region is selected from the human cDNA beginning at about100 nt downstream of the start codon. Sequences can be searched forAA(N19)TT with approximately 40-60% G/C content. AA(N19) should matchexactly the sequence of sense cDNA. The sequence of the sense siRNAcorresponds to (N19)TT or N21, respectively. N19 exactly matches thesequence of sense cDNA. A blast search should be performed on theselected siRNA against genebank full-length genes and ESTs to ensurethat only one gene is targeted. The sequence of the siRNA should beselective to the target sequence.

Preparation of the siRNA Duplexes

The siRNA duplexes used for delivery to cells can be prepared asfollows. Approximately 0.02 to 0.2 μM of the synthetic siRNAs can beused for delivery to various types of cells such as HeLa cells, Jurkat Tcells, lymphocytes, HUVEC cells and fibroblasts. SiRNAs can be obtainedfrom a number of sources including Dharmacon (Lafayette, Colo.) andAmbion (Austin, Tex.). The siRNA can be prepared by synthesizing thesense and antisense strand 21-nt oligos, followed by annealing of thesingle standed oligos. The siRNA can be incubated, pelleted andquantified using UV spectroscopy methods understood and used in the art.

Delivery of siRNA to Cells and Transfection of siRNA Duplexes

Delivery of siRNA to cells can be performed according to celltransfection methods commonly used in the art. Elbashir S M et al,Nature, 2001, 411, 494-498; McManus M T et al, J. Immunol. 2002,169:5754-60; Barton G M et al, Proc. Natl. Acad. Sci. (2002) 99:14943-5.Delivery of siRNA can be performed on various types of tissue culturecells. Preferably tissue culture cells of autoimmune or inflammatorysignificance such as lymphocytes, epithelium cells and endothelial cellsshould be used. More specifically cells such as HeLa cells, Jurkat Tcells, lymphocytes, HUVEC cells and fibroblasts. SiRNA can be deliveredto tissue and organisms as well. Lewis D L et al, Nat. Genet. (2002)32:107-8; McCaffrey A P et al, Nature (2002) 418:38-39.

Various transfection reagents can be used for siRNA delivery such aslipids-mediated transfection, electroporation or virus. In the preferredmethod the transfection reagent is OLIGOFECTAMINE™ available fromInvitrogen (Carlsbad, Calif.). Transfection efficiencies should bebetween 40 and 100%.

For each sample between about 1 to 10 μg of siRNA duplex and about 100μl of to Opti-MEM are mixed. In a separate tube 1 volume ofOligofectamine and 4 volumes of Opti-MEM are incubated from about 10 to15 minutes at room temperature. The samples are then mixed and incubatedfor another 20 to 25 minutes at room temperature. Then 16 volumes offresh Opti-MEM is added. SiRNA-transfection reagent is added to culturedcells (40 to 50% confluent). The cells are seeded for about 24 hoursprior in antibiotics-free medium using culture techniques commonly usedin the art.

A knockdown effect should be found between 1 to 5 days after delivery ofthe siRNA. The amount of knockdown is generally 40 to 100% of normalmRNA levels, and most preferably 60 to 100% of normal mRNA levels.

Treatment of cells with a proinflammatory agent In order to measure theextent of inhibition of NF-κB dependent proinflammatory genes,proinflammatory agents are administered to the cell. Acceptableproinflammatory agents are compounds that induce expression ofproinflammaotry genes under the NF-κB pathway. Proinflammatory agentsinclude but are not limited to TNFα, IL-1 and LPS. The preferredproinflammatory agent is TNFα. It is understood that otherproinflammatory agents may effect expression of NF-κB dependent genes.The stimulation time and the amount of proinflammatory agent that isused will vary according to the agent used but will be an amountsufficient to elicit a measurable proinflammatory response. TNFα isadded to the cells with about 1 to 10 ng/ml for 30 minutes to 24 hours.Typically, the proinflammatory agent is added before the measurement ofproinflammatory genes is taken.

Preparation of RNA and PCR Primers

The level of gene knockdown or inhibition of gene transcription can bemeasured by analysis of mRNA from total RNA samples. Total RNA can beprepared between about 24 and 72 hrs after delivery siRNA using methodsknown to those skilled in the art. [www.invitrogen.com/transfection].Preferably total cellular RNA is isolated from tissue or cell samplesusing the RNeasy™ kit and Rnase-Free DNase Set Protocol from Qiagen(Valencia, Calif.) according to the manufacturer's description.

TaqMan Real-Time PCR Procedures

PCR analysis can be used to analyze the isolated RNA and quantify theeffects of the IKKα inhibitor on the transcription of NF-κB dependentgenes. PCR primers and/or probes used for the measurement of thetranscription level of these genes can be prepared using techniques thatare commonly used in the art. PCR primers should be designed for theamplification of the cDNA sequence from genes of interest. Software canbe used to assist in designing design primers specific for target genes.Preferred software is Primer Express 1.5 Software (Applied Biosystems(Foster City, Calif.). Probes can be labeled with reporter agents suchas fluorescent dye, FAM (6-carboxyfluorescein) at the 5′ end and afluorescent dye quencher TAMRA (6-carboxy-tetramethyl-rhodamine) at the3′ end. Other reporter agents commonly used in the art such as P³², S³⁵fluorescein and Biotin can also be used. The specificity of PCR primerscan be tested under normal PCR conditions in a thermal cycler prior toPCR quantitation. Total cellular RNA isolated from tissue or cellsamples are used in reverse transcription (RT) reactions.

A “standard curve” can be constructed by plotting the C_(t) vs. theknown copy numbers of the template in the standard. According to thestandard curve, the copy numbers for all unknown samples are obtainedautomatically. To determine the copy numbers of the target transcript, ahuman genomic DNA (Clontech (Palo Alto, Calif.) can be used to generatea standard curve. The copy numbers of genomic DNA template arecalculated according to the molecular weight of human diploid genome[3×10⁹ bp=3×10⁹×660 (M.W.)=2×10¹² g], and then 1 μg/μl genomic DNA isconverted into 2.4×10⁶ copy numbers based upon the Avogadro's number (1mol=6.022×10²³ molecules). Serial dilutions of the samples can be run inorder to establish an estimate of the copy numbers. Copy numbers can benormalized to GAPDH or other housekeeping genes to minimize variabilityin the results due to differences in the RT efficiency and RNA integrityamong test samples.

Microarray Studies

Analysis of the transcription levels of genes can also be performedusing microarray or cRNA chip analysis. These technologies allow theanalysis of multiple genes in a single experiment. Preparation of cRNA,hybridization are performed according to methods as described herein andas otherwise commonly used in the art. Microarray analysis can beperformed using procedures available from various companies such asAffymetrix and Agilent technologies.

The Affymetrix procedure is the preferred method and is performedessentially as follows: Between 5 and 10 micrograms of the total RNA canbe converted into double stranded cDNA by reverse transcription using acDNA synthesis kit. The preferred kit for cDNA synthesis is SuperscriptChoice™, Invitrogen (Carlsbad, Calif.)) which has a special oligo (dT)24primer) (Genset, La Jolla, Calif.) containing a T7 RNA polymerasepromoter site added 3′ of the poly T tract. After second strandsynthesis, labeled cRNA is generated from the cDNA samples by an invitro transcription reaction using a reporting reagent such asbiotin-11-CTP and biotin-16-UTP (Enzo, Farmingdale, N.Y.). Labeled cRNAcan be purified by techniques commonly used in the art. The preferredmethod is to use RNeasy spin columns (Qiagen, Valencia, Calif.). About10 to 3 micrograms of each cRNA sample can be fragmented by mildalkaline treatment. Preferably, the cRNA sample is fragmented bytreatment at 94° C. for 35 minutes in fragmentation buffer as suggestedby the manufacturer. A mixture of control cRNAs for bacterial and phagegenes should be included to serve as tools for comparing hybridizationefficiency between arrays and for relative quantitation of measuredtranscript levels. Before hybridization, the cRNA samples are heated atabout 94° C. for 5 minutes, equilibrated at 45° C. for 5 minutes andclarified by centrifugation (14,000×g) at room temperature for 5minutes. Aliquots of each cRNA sample are hybridized to arrays,according the manufacturer's directions. The arrays were then washedaccording to methods according to the manufacturer. The preferred washis with non-stringent (6×SSPE, 0.01% Tween-20, 0.005% antifoam) andstringent (100 mm MES, 0.1M NaCl, 0.01% Tween 20), stained withR-Phycoerythrin Streptavidin- (Molecular Probes, Eugene, Oreg.), washedagain and scanned by an argon-ion laser scanner with the 560-nmlong-pass filter (Molecular Dynamics; Affymetrix, Santa Clara, Calif.).Data analysis can be performed in order to determine if a geneexpression level is increased, decreased or unchanged. Preferably,software such as MAS 5.0 software (Affymetrix, Santa Clara, Calif.) isused.

Identification of Ikkα Inhibitor Compounds

Another embodiment of the invention provides a method for identifying acompound for the treatment of autoimmune and inflammatory disease, saidmethod comprised of the steps of:

-   -   1) incubating an IKKα protein in the presence of a potential        inhibitor of IKKα activity;    -   2) measuring the loss of IKKα activity;    -   3) comparing the amount of IKKα activity present in the absence        of a potential inhibitor.

Compounds that are inhibitors of IKKα expression or IKKα activity foruse in the treatment of autoimmune and inflammatory disease can beidentified using the method of the invention. IKKα activity can bemeasured by determining the level of phosphorylation of the IκB protein.Li, J. et al, 1998, J. Biol. Chem. 273:30736-41. A potential inhibitorof IKKα can be siRNA directed to IKKα or other small molecule inhibitorcompounds that interact with the IKKα protein. Using the method of theinvention siRNA directed to IKKα is delivered to cells according to themethods described herein or methods known in the art. In the case ofsiRNA inhibitors, the inhibitor compound does not have to be incubatedwith the IKKα protein. Compounds whose inhibitory activities aredependent on interaction with IKKα protein should be incubated with theIKKα protein. It is understood that the IKKα siRNA does not have to beincubated with the IKKα protein in embodiments for identifying compoundsfor the treatment of autoimmune and inflammatory disease since IKKαsiRNA inhibits IKKα protein activity without interacting or contactingthe IKKα protein. The method of the invention can be practiced usingcompounds that interact with IKKα protein and inhibit IKKα proteinactivity as well as using compounds that inhibit IKKα protein activityby inhibiting IKKα expression. After incubation and/or delivery of thepotential inhibitor compound IKKα activity can be measured and thencompared to the amount of IKKα activity present.

This invention is further exemplified by the following examples whichshould not be construed as limiting. The contents of all references,patents and published patent applications cited throughout thisapplication, as well as the figures and sequence listing are herebyincorporated by reference. IKKα inhibitor compounds should be specificto IKKα. Preferably IKKα inhibitor compounds are specific for IKKα overanother IKKα protein when there is at least 10 to 100 fold or greaterand most preferably about 100 fold difference in inhibition of the IKKαcompared to IKKβ.

The present invention also includes pharmaceutical compositions andformulations which include siRNA compounds as described herein. Thepharmaceutical compositions can be administered topically, byinhalation, oral or parenteral as taught in U.S. Pat. No. 6,395,545,incorporated herein by reference. A preferred method of administrationis as an emulsion or microemulsions. Another method of administration isthrough use of liposomal formulations. Another method of administrationusing a “high pressure” delivery of RNAI into mammalian organs may alsobe used. See Nature Genetics Vol. 32 p 107-108 incorporated herein byreference.

Example 1 Preparation of siRNA Duplexes

SiRNA directed to IKKα sequence was designed according to the techniquedescribed by Tuschl. Elbashir S M et al, Nature, 2001, 411, 494-498.SiRNA duplexes composed of 21 nt sense and 21 nt antisense strands,paired in a manner to have a 2-nt 3′ overhang were used. The sequence ofthe 2-nt overhang is thought to make a contribution to the specificityof the target recognition restricted to the unpaired nucleotide adjacentto the first base pair. 2-Deoxynucleotides were used in the 3′ overhang.

The targeted region was selected from the cDNA for human IKKα shown inSEQ. ID No. 1 beginning 100 nt downstream of the start codon. Sequenceswere searched for AA(N19)TT and with approximately 50% G/C content. Thesequence of the sense siRNA corresponded to (N19)TT to N21,respectively. The 3′ end of the sense RNA was converted to TT. A blastsearch was performed on the selected siRNA against EST libraries toensure that only one gene was targeted. The sequences selected are shownas SEQ. ID Nos. 2-7.

Approximately 0.2 micromoles of the synthetic siRNAs were obtained fromDharmacon Research Inc. (Lafayette, Colo.). The siRNAs were desalted anddeprotected by the supplier and therefore were not further gel purified.The siRNA oligos were annealed and shipped in 4 tubes. Each tube wasadded 1 ml sterile RNase-free water to make 20 μM siRNA concentrations.After 1 to 2 hours of incubation on ice the siRNAs were ready for use intransfection.

Example 2 Delivery of siRNA to HeLa Cells

Transfection of siRNA Duplexes

Delivery of siRNA duplexes was performed with OLIGOFECTAMINE™ reagentavailable from Invitrogen (Carlsbad, Calif.). The samples were preparedin a 6 well format. Transfection efficiencies were found to be about80%.

For each well of a 6 well plate, one tube containing 10 μl of 20 μMsiRNA duplex with 90 μl of Opti-MEM, and in a separate tube 4 μl ofOLOGOFECTAMINET™ reagent with 96 μl of Opti-MEM were mixed and incubatedfor 7-10 minutes at room temperature. The two tubes were combined andincubated for another 20 to 25 minutes at room temperature. Then 800 μlof fresh Opti-MEM was added to obtain a final solution of 1000 μl. Then1000 μl of siRNA-OLIGOFECTAMINE™ was added to cultured cells (40 to 50%confluent). The cells were seeded the previous day in 6-well plates at adensity of 2×10⁵ cells/well using 2 ml of DMEM tissue culture mediumsupplemented with 10% FBS without antibiotics. The control used fortransfection was inverted siRNA. A knockdown effect was generally foundafter 1-2 days.

Example 3 Preparation of RNA and PCR Primers

Total RNA was prepared from the cells 2 days after delivery of siRNA's.Total cellular RNA was isolated from tissue or cell samples using theRNeasy™ kit and Rnase-Free DNase Set Protocol from Qiagen (Valencia,Calif.) according to the manufacturer's directions. PCR primers andTaqMan probes were designed using Primer Express 1.5 Software (AppliedBiosystems, Foster, Calif.). The sequence of the PCR primers used wereSEQ. ID. No. 9: 5′-GCACAGAGATGGTGAAAATCATTG-3′, and SEQ. ID. No. 10:5′-CAACTTGCTCAAATGACCAAACAG-3′. The probe sequence SeQ. ID No. 11:5′-TGAGCACACGGTCCTGACTCTGCA labeled with a reporter fluorescent dye, FAM(6-carboxyfluorescein), at the 5′ end and a fluorescent dye quencherTAMRA (6-carboxy-tetramethyl-rhodamine) at the 3′ end. The specificityof PCR primers was tested under normal PCR conditions in a thermalcycler prior to TaqMan PCR quantitation. Total cellular RNA was isolatedfrom cell samples using the RNeasy Kits and RNase-Free DNase SetProtocol according to the manufacturer's description (Qiagen). Reversetranscription (RT) reactions were carried out for each RNA sample inMicroAmp reaction tubes using TaqMan reverse transcription reagents.Each reaction tube contained 500 ng of total RNA in a volume of 50 μlcontaining 1× TaqMan RT buffer, 5.5 mM MgCl₂, 500 μM of each dNTP, 2.5μM of Random Hexamers or oligo-d(T)₁₆ primers, 0.4 U/μl of RNaseinhibitor, and 1.25 U/μl of MultiScribe Reverse Transcriptase. RTreactions were carried out at 25° C. for 10 mM, 48° C. for 40 mM and 95°C. for 5 min. Real-time PCR was performed in a MicroAmp Optical 96-WellReaction Plate (Applied Biosystems). Each well contained 2 μA of each RTproduct (20 ng total RNA), 1× TaqMan buffer A, 5.5 mM MgCl₂, 200 μMdATP/dCTP/dGTP, 400 μM dUTP, 200 nM primers (forward and reverse), 100nM TaqMan probe, 0.01 U/μl AmpErase, and 0.025 U/μl AmpliTaq™ Gold DNApolymerase in a total volume of 254 Each well was closed with MicroAmpOptical caps (Applied Biosystems), following complete loading ofreagents. Amplification conditions were 2 min at 50° C. (for AmpEraseUNG incubation to remove any uracil incorporated into the cDNA), 10 minat 95° C. (for AmpliTa™ Gold activation), and then run for 40 cycles at95° C. for 15 s, 60° C. for 1 min. All reactions were performed in theABI Prism 7700 Sequence Detection System for the test samples,standards, and no template controls. They were run in triplicates usingthe Sequence Detector V1.6 program. The Rr, and C_(t) were averaged fromthe values obtained in each reaction. A “standard curve” was constructedby plotting the C_(t) vs. the known copy numbers of the template in thestandard. According to the standard curve, the copy numbers for allunknown samples were obtained automatically. To determine the copynumbers of the target transcript, a human genomic DNA (Clontech, PaloAlto, Calif.) was used to generate a standard curve. The copy numbers ofgenomic DNA template were calculated according to the molecular weightof human diploid genome [3×10⁹ bp=3×10⁹×660 (M.W.)=2×10¹² g], and then 1μg/μl genomic DNA was converted into 2.4×10⁶ copy numbers based upon theAvogadro's number (1 mol=6.022×10²³ molecules). The genomic DNA wasserially (every ten-fold) diluted at a range of 5×10⁵ to 5×10° copynumbers. Each sample was run in triplicates, and the Rr, (the ratio ofthe amount of reporter dye emission to the quenching dye emission) andthreshold cycle (CO values were averaged from each reaction. The copynumbers were then normalized to GAPDH to minimize variability in theresults due to differences in the RT efficiency and RNA integrity amongtest samples.

Example 4 Microarray Studies Using Affymetrix

Preparation of cRNA and Gene Chip Analysis.

Preparation of cRNA, hybridization and scanning of the U133A wereperformed according to the manufacturer's protocol (Affymetrix, SantaClara, Calif.). Briefly, 5-10 μg of the total RNA was converted intodouble stranded cDNA by reverse transcription using a cDNA synthesis kit(Superscript Choice™, Invitrogen Carlsbad, Calif. with a specialoligo(dT024 primer) (Genset, La Jolla, Calif.) containing a T7 RNApolymerase promoter site added 3′ of the poly T tract. After secondstrand synthesis, labeled cRNA was generated from the cDNA samples by anin vitro transcription reaction supplemented with biotin-11-CTP andbiotin-16-UTP (Enzo, Farmingdale, N.Y.). The labeled cRNA was purifiedby using RNeasy spin columns (Qiagen, Valencia, Calif.). Fifteenmicrograms of each cRNA sample was fragmented by mild alkaline treatmentat 94° C. for 35 minutes in fragmentation buffer (40 mM Tris-acetate, pH8.1, 100 mM potassium acetate, 30 mM magnesium acetate) and then used toprepare 0.3 ml of master hybridization mix (100 mM MES, 1M [NaCl], 20 mmEDTA, 0.01% Tween 20, 0.1 mg/ml herring sperm DNA (Promega, Madison,Wis.), 0.5 mg/ml acetylated BSA (Invitrogen Carlsbad, Calif.). A mixtureof control cRNAs for bacterial and phage genes available from themanufacturer was included in the mix (BioB, BioC, BioD, and cre, at 1.5,5, 25 and 100 μM, respectively) to serve as tools for comparinghybridization efficiency between arrays and for relative quantitation ofmeasured transcript levels. Before hybridization, the cRNA samples wereheated at 94° C. for 5 minutes, equilibrated at 45° C. for 5 minutes andclarified by centrifugation (14,000×g) at room temperature for 5 min.Aliquots of each sample (10 μg of cRNA in 200 μl of the master mix) werehybridized to U133A arrays (Affymetrix) at 45° C. for 16 h in arotisserie oven set at 60 rpm. The arrays were then washed withnon-stringent (6×SSPE, 0.01% Tween-20, 0.005% antifoam) and stringent(100 mm MES, 0.1M NaCl, 0.01% Tween 20), stained with R-PhycoerythrinStreptavidin- (Molecular Probes, Eugene, Oreg.), washed again andscanned by an argon-ion laser scanner with the 560-nm long-pass filter(Molecular Dynamics; Affymetrix). Data analysis was performed by usingMAS5.0 software (Affymetrix, Santa Clara, Calif.). The software includesalgorithms that determine whether a gene is absent or present (absolutecall) and whether the expression level of a gene in an experimentalsample is significantly increased or decreased (difference call)relative to a control sample. To assess differences in gene expression,Affymetrix used the “Signal Log Ratio Algorithm” which calculates signallog ratio values using a one-step Tukey's Biweight method by taking amean of the log ratios of probe pair intensities across the two arrays.Fold change values were calculated using the following formula:2^(Signal Log Ratio), if Signal Log Ratio≧0;(−1)*2^(−(Signal Log Ratio)), if Signal Log Ratio<0 (Affymetrix GeneChipExpression Analysis manual).

Example 5 Inhibition of IKKα Gene Expression by siRNA Directed to IKKαin HeLa Cells

FIG. 1 demonstrates that siRNA of IKKα inhibits mRNA expression of IKKαin HeLa cells. HeLa cells were transfected with IKKα_(—)3 (SEQ. ID. NO.2) or IKKα_(—)3vt inverted control of oligos of IKK_(—)3 (SEQ. ID. No.3). by OLIGOFECTAMINE™ using the methods described herein. IKKα mRNAcopy numbers were determined by TaqMan™. A 3 fold reduction was found insamples receiving the siRNA relative to samples that had received thecontrol.

Example 6 IKKα SiRNA does not Inhibit IKKβ Expression

IKKα_(—)3 siRNA specifically inhibited the mRNA expression of IKKα buthad no effect on IKKβ mRNA expression as shown in FIG. 1 and Table I.This is expected since the sequence of IKKα siRNA was designed tospecifically target IKKα mRNA but not the IKKβ mRNA. Thus, IKKα_(—)3siRNA is demonstrated to be a specific IKKα inhibitor with no crossingactivity towards IKKβ.

Example 7 Inhibition of IKKα Expression Modulated the Expression ofOther Genes in the NF-κB Pathway

Table 1 shows selected IKKα-regulated genes listed in order of theirmRNA fold changes in 2 hr TNFα stimulated HeLa cells treated with IKKαsiRNA (IKKα_(—)3) vs. 2 hr TNFα stimulated HeLa cells treated withinverted control siRNA. Data were obtained by DNA microarray studiesusing Affymetrix U133A chips. Results from two independent chiphybridizations are shown. The mRNA of IKKβ and house keeping genes suchas beta Actin and GAPDH were not affected by IKKα siRNA (NC, no changecall by Affymetrix MAS 5.0 analysis) Inhibition of IKKα expression byIKKα-3 siRNA decreased the expression of known NF-κB-dependent genessuch as IL-6, IL-8, IL-11, Cox-2, Dihydrodiol dehydrogenase 1,TNF-induced proteinIntegrin, Urokinase-type plasminogen activatorreceptor; Intercellular adhesion molecule 1 (CD54), Bone morphogeneticprotein 2, Interferon-stimulated protein, 15 kDa, Superoxide dismutase 2and GRO1. These genes are understood to be NF-κB targets. Pahl H L,Oncogene (1999)18, 6853-6866; Li X et al, 2002, J. Biol. Chem., 277:45129-45140.

TABLE 1 Fold changes (IKKα siRNA + TNF_vs_ctrl siRNA + TNF) TNFAccession Gene name Exp. 1 Exp. 2 stimulation M13436 Inhibin, beta A−10.6  −7.4 Yes NM_002133 Heme oxygenase −5.5 −5.9 No (decycling) 1AF043337 Interleukin 8 −2.5 −2.3 Yes NM_001353 Dihydrodiol −2.3 −1.9 NOdehydrogenase 1 NM_014350 TNF-induced protein −2.2 −1.8 Yes NM_002205Integrin, alpha 5 −2.0 −2.3 No AY029180 Urokinase-type −1.9 −1.8 Noplasminogen activator receptor NM_000201 Intercellular adhesion −1.7−2.0 Yes molecule 1 (ICAM1/CD54) M24915 CD44 antigen −1.6 −1.7 YesAA583044 Bone morphogenetic −1.6 −1.4 yes protein 2 NM_000600Interleukin 6 −1.5 −1.5 Yes NM_000963 Cox2 −1.5 −1.7 Yes NM_000641Interleukin 11 −1.5 −1.6 Yes NM_005101 Interferon-stimulated −1.5 −1.6Yes protein, 15 kDa W46388 Superoxide dismutase 2 −1.4 −1.8 YesNM_001511 GRO1 oncogene −1.4 −1.5 yes M33197 GAPDH NC NC No X00351Actin, beta NC NC No AF080157 IKKα −3.1 −2.8 No AF080158 IKKβ NC NC NoNF-κB activity is modulated by inhibition of IKKα as shown in NF-κBreporter assay system.

Example 8

The inhibition of IKKα expression modulated the activity of NF-κB inNF-κB-dependent reporter assay. FIG. 3 shows that TNFα-inducedNF-κB-dependent luciferase activity was inhibited by siRNA of IKKα. ThepNF-κB-Luc plasmid contains NF-κB promoter elements which can beactivated by NF-κB. Downstream of the promoter is the luciferasereporter gene. When activation of NF-κB is induced by TNFα, NF-κB willactivate the artificial promoter and the promoter will drive theluciferase reporter gene expression. In this experiment, we used HeLacells that had been stably transfected with the pNF-κB-Luc reporter(Stratagene: 219078, La Jolla, Calif.).

Cells were transfected with siRNA as follows:

6 μg of siRNA duplex and 100 μl of Opti-MEM were mixed. In a separatetube 6 μl Oligofectamine and 24 μl Opti-MEM were incubated for 10minutes at room temperature. The samples were then mixed and incubatedfor 25 minutes at room temperature before 64 μl of fresh Opti-MEM wasadded to obtain a final solution of 200 μl. Finally, 200 μl ofsiRNA-transfection reagent was added to cultured cells seeded 24 hoursprior to the transfection in antibiotics-free medium. Two days latercells were stimulated with TNFα (10 ng/ml) for 24 hours. Cells were thenharvested and counted. 5×10⁵ cells in 100 μl of PBS were added to wellsof 96-well plate and the luciferase activity was measured by LucLiteLuciferase Reporter Gene Assay Kit (Packard BioScience. TheNetherlands). The luciferase activity was induced by TNFα (comparingIKKα_(—)3inverted+TNF vs. IKKα_(—)3inverted_unstim, FIG. 3) due toactivation of NF-κB. However, such induction was significantly reduced(˜3 fold reduction) by IKKα_(—)3 siRNA (comparing IKKα_(—)3+TNF vs.IKKα_(—)3_unstim, FIG. 3). Thus IKKα_(—)3 siRNA blocked TNFα-inducedNF-κB activity in gene transcription. The data demonstrate that IKKαplays an important role in TNFα-induced NF-κB-mediated genetranscription.

Example 9 siRNA of IKKα Inhibits IL-6 and IL-8 Expression in HeLa Cells

FIG. 2 show that siRNA of IKKα inhibits the expression ofproinflammatory genes under the influence of the genes in the NF-κBpathway including IL-6 and IL-8 in HeLa cells. HeLa cells weretransfected according to the methods described herein. An approximately2 fold reduction in the expression of IL-6 was found in TNFα stimulatedcells. In un-stimulated cells there was approximately 2 fold reductionin IL-6 mRNA. A 2.6 fold reduction in the level of IL-8 mRNA in TNFαstimulated HeLa cells was found and approximately 2.6 fold reduction wasfound IL-8 mRNA in unstimulated HeLa cells. These data show thecorrelation between the level of IKKα activity and the level ofexpression of genes that are under the influence of the NF-κB pathway.

The level of IL-6 and IL-8 have been shown to be elevated in autoimmuneand inflammatory disease conditions Ishihara K et al. Cytokine GrowthFactor Rev (2002), 13:357-68; Mukaida N, Int J Hematol (2000),72:391-81. Monoclonal antibody of IL-6 has been used for treatment forsystemic lupus erythematosus [http://www.clinicaltrials.gov/]. A fullyhuman anti-IL8 monoclonal antibody (ABX-IL8) has also been applied topatients with chronic bronchitis and COPD[http://www.clinicaltrials.gov/]. Therefore, the treatment ofinflammatory disease by inhibitors IL-6-IL-8 activity is demonstrated asa method for testing representative autoimmune and inflammatorydiseases.

In addition to IL-6 and IL-8 which are important targets forinflammatory diseases and autoimmune diseases (see above), many otherIKKα-regulated genes (Table I) are also mediators of inflammatorydiseases and autoimmune diseases.

Cyclooxygenase 2 (Cox2), also known as prostaglandin endoperoxidesynthase 2, is the key enzyme required for the conversion of arachidonicacid to prostaglandins which regulate immunity and inflammation (HarrisS G et al (2002) Trends in Immunology. 23:144-50; Turini M E and DuBoisR N. (2002) Annual Review of Medicine. 53:35-57). Cox2 mediatesinflammation and selective Cox2 inhibitors have been shown to be potentantiinflammatory agents (Rodrigues C R. et al, 2002, Current MedicinalChemistry. 9:849-67).

Inhibin, beta A (Activin A) is a member of the transforming growthfactor beta (TGF-beta) superfamily and functions in inflammatorypathways. Jones K L. et al (2000) Endocrinology 141:1905-8; Yu, J. et al(1997) Cytokines Cellular & Molecular Therapy. 3:169-77. There iscorrelation between inhibin secretion and damage of seminiferous tubulesin a model of experimental autoimmune orchitis (Suescun M O. et al,2001, Journal of Endocrinology 170:113-20).

Adhesion molecules such as /intercellular adhesion molecule-1 (ICAM1),integrin alpha 5, CD44 and Gro1 are important players in autoimmunityand inflammatory responses. Long-term reversal of establishedautoimmunity was observed upon the transient blockade of the LFA-ICAMpathway. Bertry-Coussot, L. et al (2002) Journal of Immunology168:3641-8. Blockade of the ICAM1 and LFA-1 interaction is an effectiveapproach for immunosuppression. Yusuf-Makagiansar H. et al (2002)Medicinal Research Reviews 22:146-67. Integrin alpha 5 is one componentof the alpha 5 beta 1 integrin which mediates integrin-independentneutrophil recruitment to endotoxin-induced lung inflammation. Burns JA. et al (2001) Journal of Immunology 166:4644-4649. Alpha 5 beta 1integrin activates an NF-κB-dependent program of gene expressionimportant for angiogenesis and inflammation. Klein S et al (2002)Molecular & Cellular Biology 22:5912-22. CD44, a cell-adhesion moleculethat is ubiquitously expressed on leukocytes and parenchymal cells,functions in several inflammatory diseases. Pure E. et al (2001) Trendsin Molecular Medicine 7:213-21. Functional activation of lymphocyte CD44in peripheral blood is a marker of autoimmune disease activity. EstessP. et al (1998) Journal of Clinical Investigation 102:1173-82.Antibodies to CD44 prevent central nervous system inflammation andexperimental encephalomyelitis by blocking secondary leukocyterecruitment. Brocke S. et al (1999) Proceedings of the National Academyof Sciences of the United States of America 96:6896-901.

1-9. (canceled)
 10. An siRNA composition comprising SEQ. ID NO. 2.11-24. (canceled)
 25. An siRNA composition comprising SEQ. ID NO. 2wherein said siRNA is synthetically made.
 26. An siRNA compositionconsisting of SEQ. ID NO. 2 and its full complement.